Achieving drug-free tolerance or successfully using only small doses of immunosuppression is a major goal in organ transplantation. To investigate the potential mechanisms by which some kidney transplant recipients can achieve operational tolerance, we compared the expression profiles of microRNA in peripheral blood mononuclear cells of operationally tolerant patients with those of stable patients treated with conventional immunosuppression. B cells from operationally tolerant patients overexpressed miR-142-3p. The expression of miR-142-3p was stable over time and was not modulated by immunosuppression. In Raji B cells, overexpression of miR-142-3p modulated nearly 1000 genes related to the immune response of B cells, including potential miR-142-3p targets and molecules previously identified in the blood of operationally tolerant patients. Furthermore, our results suggested that a negative feedback loop involving TGF-b signaling and miR-142-3p expression in B cells may contribute to the maintenance of tolerance. In summary, miR-142-3p expression in peripheral blood mononuclear cells correlates with operational tolerance. Whether upregulation of miR-142-3p modulates inflammatory responses to promote tolerance or is a result of this tolerance state requires further study.
The use of minimal doses of immunosuppression or even achievement of drug-free tolerance is a major goal in organ transplantation. 1, 2 Although the kidney is less susceptible to successful immunosuppressive drug withdrawal than the liver, where around 20% of transplant patients can be successfully weaned off immunonsuppression, 3, 4 an increasing number of kidney transplant recipients who continue to display good graft function in the absence of immunosuppressive drugs have been described in the literature. [5] [6] [7] [8] We and others have looked at the gene expression profile in PBMCs of such "operationally tolerant" kidney transplant recipients. [7] [8] [9] [10] [11] [12] The blood is a popular choice for analysis because it provides a noninvasive means for potential biomarker discovery, which is important in the case of tolerance; performing biopsies in such patients can be challenging in terms of ethical considerations and patient adherence. In these different studies, several key pathways were highlighted, such as a pathway implicating the TGF-b gene; 10 in addition, several other genes have been highlighted as "key leader genes," such as BANK-1 (B-cell scaffold protein with ankyrin repeats 1), 11 a modulator of B-cell hyperactivation through AKT upon CD40 activation. 13 The implication of B-cell-related genes correlated with a high number of B cells 14 and to a gene signature enriched in B-cell-related genes in the blood of operationally tolerant kidney recipients, which was subsequently confirmed in three different studies. 7, 8, 12 The role of B cells has also been reported in experimental rodent models, in which transfer of B cells from tolerant rats prolonged graft survival when administered to untreated recipients. 15 The mechanisms involved in the maintenance of this phenomenon remain elusive, and the identification of related biomarkers remains instrumental to achieving safe drug minimization or complete weaning in clinical practice.
miRNA are small, endogenous, noncoding RNAs that can regulate the expression of a variety of genes by directly destabilizing their target mRNA. 16, 17 Furthermore, the incomplete pattern of target recognition allows a single miRNA to target hundreds of mRNAs, and conversely, a single mRNA to be targeted by multiple miRNAs, thus affecting a broad range of gene networks. 18 Numerous studies have reported on the differential expression of miRNA in physiologic disorders or diseases, 19, 20 and miRNA has been found to be modulated in biopsy specimens from kidney transplant recipients. [21] [22] [23] In this study, we investigated whether miRNA is modulated in the blood of patients with operational tolerance compared with a cohort of patients with stable graft function under classic immunosuppression.
RESULTS

miRNA Profiling in PBMC from Kidney Transplant Recipients
We first searched for a global miRNA profile in PBMCs from kidney transplant recipients using miRNA Taqman lowdensity arrays (TLDAs). The expression of 381 miRNAs was measured in PBMCs from 9 operationally tolerant patients and 10 STA recipients. A total of 266 miRNAs were expressed with a quantification cycle (Cq) inferior to 35 in at least half of samples from each group. We selected the eight top-ranked miRNAs on the basis of Mann-Whitney tests between the two groups of patients ( Figure 1, A and B) . According to the expression values of these eight miRNAs, the clear separation of the two groups of patients by clinical status was further observed using principal component analysis (Supplemental Figure 1) . Among the eight differentially expressed miRNAs, four were overexpressed (miR-450b-5p, miR142-3p, miR-876-3p, and miR-106b) and four were underexpressed (miR508-3p, miR-148b, miR-324-5p, and miR-98) in PBMCs from operationally tolerant compared with STA patients.
miRNA Profiling in PBMCs from Healthy Volunteers after Polyclonal Activation
To further analyze the basal expression and modulation of these eight specific miRNAs, we performed miRNA profiling in PBMCs from healthy volunteers before and 24 hours after phytohemagglutinin A (PHA) and IL-2 stimulation (Supplemental Figure 2 ). Fifty-two miRNAs displayed a fold change (FC) superior to 2 (i.e., log 2 FC.1) and 59 others, an FC inferior to 2 (i.e., log 2 FC.-1), indicating a strong modulation of expression after PHA/IL-2 stimulation (Supplemental Table 5 and Supplemental Figure 2 ). Among the eight miRNAs differentially expressed between operationally tolerant and STA recipients, miR-450b-5p, miR-142-3p, and miR-324-5p were downregulated (FC=0.21, 0.29, and 0.42, respectively; Figure  1B ) and miR-876-3p was upregulated (FC=3.4; Figure 1B ) after PHA/IL-2 stimulation. We confirmed the downregulation of miR-142-3p as early as 2 hours and at 24 hours after PHA/IL-2 stimulation, using individual Taqman microRNA assays (Figure 2A) .
Because miR-142-3p (1) appeared as the highest differentially expressed miRNA between operationally tolerant and STA recipients, (2) was underexpressed after PHA/IL-2 stimulation ( Figure 2A) , (3) is specific to the hematopoietic lineage, [24] [25] [26] and (4) plays a role in lymphocyte functions, 27 we focused on the potential role of this miRNA in our study. This miRNA is overexpressed in operationally tolerant compared with STA patients according to TLDA assays ( Figure 1C ).
Validation of miR-142-3p Overexpression and Stability over Time in PBMCs from Operationally Tolerant Recipients
Individual miR-142-3p Taqman quantitative PCR (qPCR) assays displays a good correlation (r=0.885; P,0.0001) ( Figure  1D ). Furthermore, we validated the overexpression of miR-142-3p in operationally tolerant recipients on 16 independent PBMC samples (6 operationally tolerant and 10 STA patients) (P=0.02; FC=1.58) ( Figure 2B ). The post-transplantation time was significantly higher in operationally tolerant than in STA patients (P=0.02; Table 1 ); however, we did not found any correlation between this time and miR-142-3p expression value (r=0.0342; P=0.845; Supplemental Figure 3 ). No significant difference was observed between the subgroups of patients for any of the clinical variables tested (age, sex, creatine level in blood, proteinuria, number of HLA mismatches). Finally, the expression of mir-142-3p was stable over time, as tested in PBMCs collected from three operationally tolerant recipients at two different time points (5.5, 11, and 13 months) ( Figure 2C ).
Overexpression of miR-142-3p in the Blood of Operationally Tolerant Recipients Is Not Due to the Absence of Immunosuppression Because operationally tolerant patients display stable graft function but no longer receive immunosuppression and because healthy volunteers also displayed an increased expression of miR-142-3p compared with STA patients (P=0.0038; FC=1.54) (data not shown), we hypothesized that immunosuppression treatment may modulate the blood expression of miR-142-3p. We thus measured its expression in PBMCs from tolerant liver transplant recipients before and after the patients entered an immunosuppressive drug weaning protocol (n=27), a population not available in the context of kidney transplantation. No difference was found in the PBMC expression of miR-142-3p with or without immunosuppression regimen in these liver recipients ( Figure 2D ).
miR-142-3p Is Overexpressed in B Cells from Operationally Tolerant Patients
We then analyzed the expression of miR-142-3p in purified blood leukocyte subpopulations (T and B lymphocytes, monocytes, and NK cells) from healthy volunteers (n=3). Purification was typically greater than 95%. Figure 3A shows that miR-142-3p is expressed in all blood cell subsets, confirming previous reports. [24] [25] [26] Because miR-142-3p was highly expressed in T and B lymphocytes from healthy volunteers, we next analyzed its expression in these two populations in transplant recipients. No difference was observed in the expression of miR-142-3p in the T lymphocyte subset ( Figure 3C ). In contrast, the expression of miR-142-3p was significantly higher in total B cells purified from operationally tolerant compared with STA recipients (P=0.01; FC= 2.84) ( Figure 3B ), whereas no difference was observed compared with healthy volunteers (data not shown). Therefore, purified B cells from healthy volunteers were cultured over 24 hours with physiologic and high doses of cyclosporine A (40 and 400 ng/ml). As shown in Figure 3D , no difference was observed for either dose of cyclosporine A used. These results are concordant with the absence of modulation of miR-142-3p in blood from livertolerant recipients before and after withdrawal of the treatment and suggest that miR-142-3p is not affected by immunosuppressive drugs in total PBMC or purified B cells.
miR-142-3p Transfection in the Raji B-Cell Line
Because miRNA regulate mRNA levels, 16, 17 we overexpressed mir-142-3p in the Raji B-cell line using synthetic mimics and performed gene expression profiling using microarrays 24 hours after transfection. A total of 22,332 spots were filtered and the overexpression of miR-142-3p was found to induce the up-and downregulation of 492 and 489 transcripts, respectively. To provide a more comprehensive biologic interpretation of our finding, GOminer software was used to identify the over-represented gene ontology (GO) categories based on the differential gene lists compared with all other expressed genes in the microarray. 28 Among the 492 overexpressed genes, the GO categories "immune response" (GO:0006955) and "B-cell activation" (GO:0042113) were identified with a total of 25 genes. Among the 489 underexpressed genes, GO categories related to cell communication (GO:0007154), "vesicle-mediated transport" (GO:0016192), and "small GTPase [guanosine triphosphatase] mediated signal transduction" (GO:0007264) were identified. We then identified 66 potential miR-142-3p targets downregulated subsequent to the miR-142-3p overexpression among the 242 genes predicted to be miR-142-3p targets (among at least 4 of 11 established miRNA target prediction databases computed by miRecords software). 29 Mixing these 66 potential target genes and the 25 upregulated immune-related genes and using Ingenuity pathways analysis software, a gene network related to "Inflammation response, antimicrobial response and cell development" with 49 of these genes was found (Supplemental Figure 4) . Within this gene network, we identified a subgroup of TGF-b-related genes in which the TGF-b receptor 1 gene (TGFBR1), a possible target of miR-142-3p, plays a central role ( Figure 4A ), together with a subgroup of IFN-g-related genes ( Figure 4B ), and a subgroup of genes related to B cells ( Figure 4C ). The analysis of the detailed B-cell-related gene network after miR-142-3p transfection highlighted the upregulation of genes previously identified in PBMCs from operationally tolerant recipients, such as the key molecules MS4A1 (CD20), CR2, CD38, 1 0 and BANK-1. 11, 12 We next validated the array expression patterns of a few select targets and miRNA expression. The upregulation of miR-142-3p, MS4A1, and BANK1 in Raji cells transfected with miR-142-3p mimics was confirmed using individual Taqman assays ( Figure 5A ).
Implication of miR-142-3p in TGF-b Pathway
Using individual qPCR, we also confirmed the significant downregulation of TGFBR1 gene transcripts subsequent to miR-142-3p transfection in the Raji cell line compared with control (P=0.03; FC=0.47; Figure 5A ). We then noted that the addition of TGF-b to the Raji culture media (5 ng/ml over 24 hours) induced an increase in miR-142-3p expression, whereas PHA stimulation did not ( Figure 5B) . Similarly, purified B cells from healthy volunteers were activated with independent and dependent B-cell receptor signaling for 24 hours ( Figure 3D ). As observed after PHA stimulation in Raji cells ( Figure 5B) , there is only nonsignificant and marginal regulation of miR-142-3p. This finding reinforces the fact that miR-142-3p needs specific stimulation, such as TGF-b, for its modulation ( Figure 5B) .
We then measured TGF-b1 and TGFBR1 transcript levels in purified B cells from operationally tolerant and STA patients. We found that TGF-b1 expression is increased in B cells from operationally tolerant patients (FC=1.4 compared with STA; P=0.04) ( Figure 5C ), whereas the level of TGFBR1 did not significantly differ between operationally tolerant and STA patients ( Figure 5D ).
DISCUSSION
The achievement of long-term drug-free tolerance in solid organ transplantation is thought to be possible on the basis of observations in both liver 4 and kidney 3, 5 transplantation. We and others have reported on an increased number of peripheral B cells and have identified modifications in blood gene expression in operationally tolerant kidney transplant recipients that involve TGF-b signaling and B-cell-related pathways. 7, 8, 10, 12, 14 However, a clear mechanism or biologic process of peripheral regulation has yet to be identified in these patients. miRNAs are small RNA molecules with important roles in immune modulation, homeostasis, the development of immune diseases and the regulation of physiologic processes. 19 Deregulated miRNA expression has been shown to be involved in several human immune-related diseases, such as multiple sclerosis, 30, 31 cancer, 32, 33 and rheumatoid arthritis, 34 but their function and regulation processes are still far from being totally understood. In renal transplantation, two studies reported on the identification of miRNA profile signatures in biopsy samples from kidney transplant patients with acute rejection episodes, 21, 23 suggesting that miRNA expression profiling may be used to monitor allograft status. To our knowledge, and particularly in operationally tolerant kidney transplant recipients, no miRNA expression analyses have been performed in the blood. In this study, we report on the modulation of expression of eight miRNAs in PBMCs from kidney graft recipients with drug-free operational tolerance compared with patients with stable graft function under immunosuppression. Our choice to compare operationally tolerant patients with patients who have stable graft function under immunosuppression was based on the fact that the latter population is the most likely to benefit from immunosuppression minimization, whereas patients with chronic rejection or healthy volunteers would not. Unsupervised hierarchical clustering analysis based on the expression of these eight miRNAs only led to the clustering of operationally tolerant patients together ( Figure 1A ). Among these eight miRNA, miR-142-3p was highly expressed in PBMCs from operationally tolerant patients ( Figure 1C and Figure 2B ). This miRNA has been described as a hematopoietic-restricted lineage miRNA. [24] [25] [26] [27] We found that miR-142-3p was decreased after PHA/IL-2 activation, further favoring a regulatory loop, as already described for other miRNAs, such as miR-125b, miR-16b, or miR-148b. [35] [36] [37] miR-142-3p expression has been reported as playing a role in CD4 + CD25 + Treg function. 27 Although miR-142-3p was highly expressed in T lymphocytes, we did not observe any differential expression in T lymphocytes between operationally tolerant and STA recipients ( Figure 3C ). In contrast, we found a significant overexpression of miR-142-3p in the B-lymphocyte subset of operationally tolerant compared with STA patients (P=0.0098; FC=2.84) ( Figure  3B ) and also compared with patients with signs of chronic antibody-mediated rejection (data not shown). We also found that its expression was not modulated by immunosuppressive treatment in tolerant liver transplant recipients ( Figure 2D ) or when purified B cells from human volunteers were cultured with cyclosporine A in vitro ( Figure 3D ), indicating that its overexpression in operationally tolerant kidney transplant recipients was not just a consequence of the absence of immunosuppression.
Interestingly, these data are in accordance with an increased number of peripheral B cells 14 and with the specific B-cellenriched gene profile that we and others previously reported in the blood of these patients. 7, 8, 10, 12 Although the increased expression of miR-142-3p in PBMCs from operationally tolerant kidney recipients is probably in part due to the increased number of blood B cells in these patients, because miR-142-3p expression in PBMCs is correlated with B cell number (data not shown), we report that purified B cells from operationally tolerant also expressed more miR-142-3p. This miRNA has already been reported to be expressed specifically in hematopoietic tissues and particularly in B cells, but a precise role in the B-cell compartment has yet to be attributed. [24] [25] [26] [27] 38 miR-142-3p expression has also been associated with tubular atrophy and interstitial fibrosis of renal transplants. 22 Moreover, miR-142-3p was overexpressed in B lymphocytes from the blood of operationally tolerant patients, and this analysis performed in peripheral blood does not exclude a different expression profile within the graft itself. In addition, we did not find any correlation between miR-142-3p expression and posttransplantation time and did find miR-142-3p expression to be stable over time ( Figure  2C) ; these results indicate that miR-142-3p is independent of post-transplantation time.
Recently, Guo and colleagues demonstrated that miRNA decreased protein production mostly by lowering mRNA levels. 17 Thus, we used gene microarrays to measure the effect of miR-142-3p overexpression in B cells, looking at the effect of experimental miR-142-3p transfection in a stable Raji B-cell line. Whereas the overexpression of this single miRNA repressed many genes, we observed the paradoxical biologic effect of miR-142-3p, which also induced gene upregulation, as already described for other miRNAs. 39 A large number of genes related to B cells, IFN-g, and TGF-b signaling were upregulated after overexpression of miR-142-3p in the Raji B-cell line. Of note, in previous studies we had already observed some of these genes, such as MS4A1 (CD20); this gene was part of the 49-gene signature that correctly classified kidney operationally tolerant patients 10 and was part of the best-classifier genes in the blood and urine of operationally tolerant patients in the study by Newell and colleagues. 7 Similarly, miR-142-3p overexpression led to the upregulation of BANK1 transcripts, one of the key leader genes upregulated in the blood of kidney operationally tolerant recipients, 11 independent of immunosuppressive treatment. 12 BANK1 is an inhibitory adaptor protein highly expressed in peripheral B cells and is a modulator of hyperactive B-cell responses by inhibiting AKT activation upon CD40 signaling. 13 Finally, the TGF-b signaling pathway was also affected after miR-142-3p overexpression in the Raji cell line and in B cells from operationally tolerant patients. Interestingly, miR-106b, one of the eight differentially overexpressed miRNA in PBMCs from operationally tolerant kidney transplant recipients, also affects downstream effector molecules of TGF-b signaling. 40, 41 In a previous report, we showed that among the specific and unique blood signature of 49 genes associated with tolerance, 27% of the genes modulated in blood from operationally tolerant patients could be regulated by the TGF-b even though TGF-b was not significantly increased in total PBMCs from operationally tolerant patients (increased from 30% only). 10 TGF-b is involved in various animal models of tolerance, [42] [43] [44] plays a role in immune regulation and homeostasis of Treg cells, 45 and is known for its intrinsic suppressive properties. 46 We also report here that TGF-b stimulation of Raji cells induced an increased expression of miR-142-3p and that TGF-b1 expression is increased in B cells from operationally tolerant patients, whereas TGFBR1 is not; this finding suggests a negative feedback loop between this cytokine and miR-142-3p in B cells. Such a process of regulation, already described for different miRNAs, 40 suggests that miRNAs act as key gene switches and as fine-tuning molecules, depending on the compartment and the specific biologic context. 20 Therefore, our data suggest that mir-142-3p is also implicated in the TGF-b pathway. However, because the modulation of one miRNA may affect multiple mRNAs that are also regulated by several other miRNAs, a direct link between these two molecules cannot be predicted at this stage. Our findings show that overexpression of miR-142-3p in B cells correlates to the state of operational tolerance in kidney transplant recipients. They also point toward a possible negative feedback loop between TGF-b and miR-142-3p in B cells. The mechanism driving and maintaining spontaneous tolerance in which TGF-b could be implicated remains unclear. Further investigations are now needed to find out whether this overexpression of miR-142-3p in B cells contributes to controlling inflammatory responses and tolerance maintenance or is only a consequence of this tolerance state.
CONCISE METHODS
Patients
A total of 86 individuals were enrolled in this study: 15 operationally tolerant patients, 34STApatients, 10 healthy volunteers, 11liver recipients with stable graft function, and 16 drug-free liver recipients from the Nantes hospital in France and the Barcelona hospital in Spain. The two local ethics committees approved all aspects of the study, and all patients gave informed consent. The clinical information is described in the Supplemental Materials and Methods, clinical data are summarized in Table  1 , and detailed clinical data are provided in Supplemental Table 6. miRNA Profiling miRNA profiling was performed using TLDA microRNACards pool A set, version 2.0 (Applied Biosystems, Foster City, CA), in accordance with the manufacturer's recommendations. Normalization was performed by subtracting the mean Cq of the measured miRNA. 47 After normalization, miRNA were ranked using P values from nonparametric Mann-Whitney tests, which do not require normal assumptions or asymptotic conditions. These uncorrected P values for multiple testing were used only for ranking miRNA and are not an absolute identification of differential miRNA.
miRNA Individual Assays
Individual miRNA expression was measured with Taqman miRNA assays (Applied Biosystems) using probes for miR-142-3p (assay ID: 000464), RNU6 (assay ID: 001973), and miR-374b (assay ID: 001319), starting with 10 ng of total RNA, on an ABI Prism 7900 HT.
Gene Expression Microarray Analysis
Gene expression was measured using whole human genome 4344K Agilent microarrays, following the manufacturer's two-color protocol (Agilent Technologies Inc., Palo Alto, CA). A total of 22,332 spots were filtered. GOminer software and Ingenuity Pathway Analysis 6.5 software (Ingenuity Systems Inc.) were used to assess biologic significance of genes selected with Mann-Whitney tests. Raw microarray data were deposited in the Gene Expression Ominbus (GEO) database (accession number GSE28456).
Statistical Analyses
The nonparametric Mann-Whitney test, Kruskal Wallis test, or paired Wilcoxon test was used for group comparisons using Graph PadPrism software, version 4. Differences were defined as statistically significant with P,0.05 and highly significant with P,0.01. Additional details can be found in Supplemental Materials and Methods.
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